Beacon Topco, Inc. completed its acquisition of Barinthus Biotherapeutics plc. on 2026-09-09, according to the Form 8-K Barinthus Biotherapeutics plc. filed with the SEC on 2026-09-09. The filing's Item 2.01 states no aggregate dollar price. Barinthus Biotherapeutics plc. filed the report because the deal made it part of Beacon Topco, Inc..
| Acquirer | Beacon Topco, Inc. |
|---|---|
| Acquired | Barinthus Biotherapeutics plc. |
| Completed | 2026-09-09 |
| Reported by | Barinthus Biotherapeutics plc. (BRNS), the company acquired |
| Filing | Form 8-K, filed 2026-09-09 |
Want the whole picture on Beacon Topco, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Beacon Topco, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Beacon Topco, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
1 cited source found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
What the filing says
On September 9, 2026 pursuant to a court-sanctioned scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the " Scheme of Arrangement ") and as contemplated by the previously announced Merger Agreement, dated September 29, 2025 (the, " Original Merger Agreement "), as amended by that certain Amendment Agreement to the Merger Agreement dated February 22, 2026 (the " Merger Agreement Amendment "), by and among Barinthus Biotherapeutics plc (the " Company "), Beacon Topco, Inc. (" Topco "), Cdog Merger Sub, Inc (" Merger Sub ") and Clywedog Therapeutics, Inc (" Clywedog ") (together with the Original Merger Agreement, the " Merger Agreement "), the entire issued and to be issued share capital of the Company was acquired by Topco and the Company became a wholly-owned subsidiary of Topco (the " Transaction ").
More from the filing
This Current Report on Form 8-K is being filed in connection with the completion of the previously announced Transaction (as described below).
As previously announced, on September 1, 2026, the High Court of Justice of England and Wales (the " Court ") sanctioned the Scheme of Arrangement and a capital reduction of the share premium account of the Company.
On September 9, 2026, the Court Order was delivered to the Registrar of Companies in England and Wales, at which time the Scheme of Arrangement became effective (the " Scheme Effective Time ").
Quoted from Barinthus Biotherapeutics plc.'s Form 8-K.
This is the only completed acquisition Beacon Topco, Inc. reported under Item 2.01 in the last twelve months, as far as the filings of the companies it bought show.
Who runs it now, who owns it, where the money comes from and what to watch for, every claim linked to its source.
Order Full Report on Beacon Topco, Inc.Look up Beacon Topco, Inc. and see what is on record before you decide.
Get the free SnapshotWhere this comes from
A public company must file a current report on Form 8-K with the SEC within four business days of completing a significant acquisition or disposition of assets, under Item 2.01 of the report. The acquired company sometimes files one too, when the deal makes it a subsidiary of the buyer.
Every fact on this page is taken from one of those filings and linked to it: which company acquired which, the date the filing gives for completion, and the price when the filing states one in dollars, shown next to the sentence that states it. A filing states what was bought and on what terms; it rarely states why, and neither does this page.